An interview with Dr ChhatwalAnadys Pharmaceuticals, Inc. today announced preliminary outcomes from an ongoing Phase II study demonstrating that 73 percent of hepatitis C sufferers treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin achieved undetectable degrees of virus at week 12, referred to as total Early Virological Response or cEVR. No patient experienced viral rebound on ANA598. The 73 percent cEVR demonstrated by ANA598 is comparable to the innovative protease inhibitors currently in advancement for HCV, stated Steve Worland, Ph.D., President and CEO of Anadys. SOURCE Anadys Pharmaceuticals, Inc.Milstein Associate Professor of Clinical Operation at Columbia University College of Doctors and Surgeons and chief of breasts surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Feldman and his co-workers at NewYork-Presbyterian/Columbia are having a technique known as bioimpedence spectroscopy to greatly help them identify the initial starting point of lymphedema. An FDA-approved gadget called L-DEX runs on the mild electrical current to measure minute changes in extracellular fluid, enabling a medical diagnosis of lymphedema by the doctor well before any swelling is certainly noticeable.